Drugmaker Johnson & Johnson has halted manufacturing of its single-dose COVID-19 vaccine, in keeping with a New York Instances report.
The pharmaceutical firm final 12 months quietly shut down manufacturing at a plant in Leiden, Netherlands, which was the one facility the place usable doses of the vaccine had been manufactured, catching a few of its prospects off guard, together with creating nations that want the single-dose J&J drug over two-dose alternate options, the report states.
Johnson & Johnson has as a substitute been utilizing the plant to work on an experimental and doubtlessly extra worthwhile drug that would defend towards an unrelated respiratory virus, in keeping with the report.
The plant is anticipated to renew manufacturing of the COVID-19 vaccine, however it’s unclear when.
J&J didn’t touch upon the plant closure studies, however stated in an announcement to CBS Information “we at present have tens of millions of doses of our COVID-19 vaccine in stock” and “we proceed to satisfy our contractual obligations … [to] the African Union.”
Vaccine of selection for poorer international locations
The J&J vaccine, known as the Janssen COVID-19 vaccine, made by Janssen Biotech, a subsidiary of Johnson & Johnson, is the vaccine of selection for poorer international locations which can be relying on the drugmaker to assist them combat the pandemic.
Wealthier nations just like the U.S. have favored photographs from Moderna and Pfizer, as a result of the 2 seem like simpler towards COVID-19 variants like Omicron, and since the Janssen vaccine has, up to now, been linked to uncommon however doubtlessly life-threatening blood clots.
On condition that just one dose of the J&J vaccine is required, although, it is inexpensive than its double-dose counterparts and in addition simpler to ship, making it fashionable in lower-income international locations.